血小板无力症 中国就医指南

Glanzmann thrombasthenia (GT) is a rare, inherited autosomal recessive bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin glycoprotein complex—also known as the fibrinogen receptor—on the platelet surface. This glycoprotein is essential for platelet binding to fibrinogen, von Willebrand factor, and other adhesive ligands during hemostasis; its dysfunction results in severely impaired platelet plug formation despite normal platelet counts and morphology. Pathogenesis stems from biallelic loss-of-function mutations in either ITGA2B (encoding αIIb) or ITGB3 (encoding β3), leading to absent, reduced, or nonfunctional αIIbβ3 receptors. As a consequence, patients exhibit prolonged bleeding time, mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), easy bruising, and excessive bleeding after trauma or surgery—though spontaneous deep tissue or intracranial hemorrhage is uncommon. GT is pan-ethnic but shows higher prevalence in populations with increased consanguinity, such as Middle Eastern, Indian, and Romani communities. Epidemiologically, GT affects approximately 1 in 1,000,000 individuals worldwide, with no gender predilection. Risk factors include parental consanguinity and family history of unexplained bleeding diathesis; genetic counseling and prenatal testing are recommended for at-risk families. Quality of life is significantly impacted: chronic anemia from recurrent bleeding may cause fatigue and reduced exercise tolerance; adolescents and women face psychosocial challenges related to menorrhagia and fear of surgical procedures; children often experience school absences due to bleeding episodes or prophylactic interventions. While GT is lifelong and currently incurable, supportive management—including antifibrinolytics (e.g., tranexamic acid), platelet transfusions (for major bleeding or surgery), recombinant activated factor VIIa (rFVIIa), and emerging therapies like gene editing and lentiviral gene therapy in clinical trials—enables most patients to achieve near-normal functional status. However, alloimmunization against αIIbβ3 following repeated platelet transfusions remains a serious complication, limiting future transfusion efficacy and increasing perioperative risk. Comprehensive care requires multidisciplinary coordination among hematologists, gynecologists, dentists, surgeons, and psychologists within specialized coagulation centers.

# 血小板无力症（Glanzmann血栓病）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：轻中度出血倾向、无严重黏膜/内脏出血、术前预防或妊娠期患者

• •一线药物：去氨加压素（DDAVP）静脉/皮下注射（单次300–600元，疗程5–10次）
• •替代支持：血小板输注（单单位2800–3500元，需HLA匹配者加收1200元/次）
• •辅助治疗：抗纤溶药（氨甲环酸口服片剂，月均120–300元）
• •必查检验：血小板功能分析（PFA-100）、流式细胞术检测GPⅡb/Ⅲa表达（1200–1800元/项）

二、手术/介入治疗方案

适用人群：反复危及生命出血、脾亢继发血小板破坏增加、药物无效者

• •脾切除术（开腹/腹腔镜）：术前需骨髓活检+免疫分型（2600–3200元），手术总费用（含麻醉、住院7–10天）：4.2万–6.8万元
• •无根治性介入手段：本病为遗传性膜糖蛋白缺陷，无血管介入或干细胞移植适应证（除非合并重型再生障碍性贫血等罕见共病）

三、特殊复杂情况处理

• •妊娠合并大出血：DDAVP联合单采血小板输注，单次总费用约1.1万–1.9万元
• •术后难控出血：重组活化凝血因子Ⅶa（rFVIIa）按公斤体重给药，单支6800元（50μg/kg），通常需2–3支

四、方案快速选择指南

• •预算≤5000元/年：DDAVP按需治疗+氨甲环酸维持
• •突发中重度出血：立即血小板输注+rFVIIa（医保限重症）
• •反复出血影响生活质量：评估脾切除术（医保报销后自付约1.3万–2.2万元）